In vitro activity of terbinafine against clinical isolates of dermatophytes. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


In vitro activity of terbinafine against clinical isolates of dermatophytes.

Med Mycol. 1998 Aug;36(4):235-7. Unique Identifier : AIDSLINE MED/99102707
Arzeni D; Barchiesi F; Compagnucci P; Cellini A; Simonetti O; Offidani AM; Scalise G; Istituto di Malattie Infettive e Medicina Pubblica, Universita; degli Studi di Ancona, Italy.

Abstract: A broth macrodilution method following the recommendations established by the National Committee for Clinical Laboratory Standards was employed for testing terbinafine against 20 clinical isolates of dermatophytes belonging to seven species. The minimal inhibitory concentrations resulting in either 80% or 100% inhibition of growth, compared to growth in drug-free control tubes, ranged from </=0.03 to 0.25 g ml-1 and from </=0.03 to 2.0 g ml-1, respectively. Terbinafine was shown to be fungicidal at a concentration of </=1.0 microg ml-1 for 19 isolates. No differences in susceptibilities were found between strains isolated from HIV-positive and -negative individuals.
Keywords: JOURNAL ARTICLE Antifungal Agents/*PHARMACOLOGY Arthrodermataceae/*DRUG EFFECTS/GROWTH & DEVELOPMENT/ISOLATION & PURIF Dose-Response Relationship, Drug Human Microbial Sensitivity Tests Naphthalenes/*PHARMACOLOGY Species Specificity Support, Non-U.S. Gov'tKWDjournalarticleantifungalagents/KWDpharmacologyarthrodermataceae/KWDdrugeffects/growth&development/isolation&purifdose-responserelationship,drughumanmicrobialsensitivitytestsnaphthalenes/KWDpharmacologyspeciesspecificitysupport,non-uKWDsKWDgov't
990530
A9950901

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .